Quantifying intratumor heterogeneity through MRI-based habitat analysis to distinguish HER2-low and HER2-zero triple-negative breast cancer
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background To evaluate whether magnetic resonance imaging (MRI)-derived intratumoral heterogeneity (ITH), quantified using habitat analysis, can distinguish human epidermal growth factor receptor 2 (HER2)-low from HER2-zero triple-negative breast cancer (TNBC), and to develop a combined model incorporating ITH, MRI features, and clinicopathological characteristics. Methods This retrospective study included patients with surgically confirmed TNBC from two medical centers between April 2019 and September 2024. Center 1 provided the training cohort and center 2 provided the external validation cohort. Preoperative dynamic contrast-enhanced MRI (DCE-MRI) and clinicopathological data were collected. Habitat maps were generated by K-means clustering of peak-enhancement-phase images, and an ITH score was calculated from the spatial distribution of habitat regions. Logistic regression was used to develop an ITH-score model, a clinical-imaging model, and a combined model. Discrimination, calibration, and potential net benefit were evaluated. Results The study included 134 patients: 96 in the training cohort and 38 in the external validation cohort. The combined model achieved an area under the receiver operating characteristic curve (AUC) of 0.827 (95% confidence interval [CI]: 0.746–0.907) in the training cohort and 0.800 (95% CI: 0.660–0.940) in the validation cohort. Corresponding AUCs were 0.786 (95% CI: 0.695–0.876) and 0.769 (95% CI: 0.612–0.927) for the ITH-score model, and 0.712 (95% CI: 0.613–0.812) and 0.747 (95% CI: 0.595–0.900) for the clinical-imaging model. The combined model showed a numerically higher validation AUC, but the between-model differences were not statistically significant. Decision curve analysis suggested potential net benefit within the evaluated threshold ranges. Conclusions The combined model showed promising discrimination between HER2-low and HER2-zero TNBC. The small external validation cohort and wide confidence interval warrant cautious interpretation. Larger prospective studies are needed before the model can inform clinical decision-making.
Source: Frontiers in Oncology
Authors: Jiayu Nan(Formal analysis, Investigation, Methodology, Writing – original draft), Hao Li(Data curation, Investigation, Methodology, Project administration, Software, Visualization, Writing – review & editing), Wei Zeng(Data curation, Investigation, Visualization, Writing – review & editing), Ao Wu(Data curation, Investigation, Resources, Writing – review & editing), Yingyi Luo(Data curation, Methodology, Resources, Writing – review & editing), Jiahui Jiang(Data curation, Investigation, Resources, Writing – review & editing), Jiale Hu(Data curation, Resources, Validation, Writing – review & editing), Lan Liu(Conceptualization, Formal analysis, Funding acquisition, Investigation, Project administration, Supervision, Writing – review & editing)
Institutions: Jiangxi Provincial Cancer Hospital, Nanchang Medical College
Language: English
Topic: MRI in cancer diagnosis
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236502916
